Join our daily newsletter At The Bell to receive exclusive market insights
- Anatara Lifesciences (ANR) has been granted an Australian patent covering the formulation for its animal health product, Detach
- Detach is a non-antibiotic therapy designed to prevent and treat diarrhoea in piglets, using an enzyme extracted from pineapples
- The granted patent strengthens Anatara’s intellectual property portfolio and will help the company progress product commercialisation opportunities
- In related news, a study of the company’s formulated feed additive in piglets has begun, with completion set for June
- Anatara Lifesciences is up 22.22 per cent and trading at 22 cents per share
Anatara Lifesciences (ANR) has been granted an Australian patent covering the formulation for its animal health product, Detach.
The company’s product, Detach, is a non-antibiotic therapy designed to prevent and treat diarrhoea in piglets — known as scour — using the enzyme bromelain, which is extracted from the stems of pineapples.
The granted patent strengthens Anatara’s intellectual property portfolio for the treatment and prevention of diarrhoea caused by pathogenic microbes. Furthermore, the patent also provides a pathway for the company to continue pursuing commercialisation opportunities for the Detach product.
The patent will expire on August 24, 2038.
Anatara’s CEO, Steven Lydeamore, commented on what the granted patent means for the company’s future.
“The granting of the patent secures our intellectual property position and is a significant milestone towards commercialising our Detach animal health product,” he said.
“Scour in piglets is an expensive, debilitating, and in some cases, life-threatening condition, and having a product that is registered for use in Australia, we are well placed to leverage our patent as we work towards a commercial deal,” he added.
In related news, the BONIFF-SMEC piglet challenge study for enterotoxigenic Escherichia Coli has begun at Murdoch University. The study, conducted in partnership with Ridley Corporation, will assess piglets given Anatara’s formulated feed additive, combined with Ridley’s semi-moist extruded creed feed.
The project will investigate the effect that this combined formulation has on the piglets’ health, welfare and performance after weaning. The study is expected to be completed in June 2021.
Anatara Lifesciences is up 22.22 per cent, trading at 22 cents per share at 10:50 am AEST.
